Capital/Financing Update • Jul 13, 2021
Capital/Financing Update
Open in ViewerOpens in native device viewer
PRESS RELEASE
Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, the following resources were listed in the liquidity account as at June 30, 2021, settlement date:
During the 1 st half of 2021, were negotiated a total of:
| BUY | 225,004 shares | € 157,757.98 | 122 executions |
|---|---|---|---|
| SALE | 203,522 shares | € 148,483.15 | 118 executions |
It is recalled that for the last half-year summary as at June 30, 2020, the following resources were included in the liquidity account:
During the 2 nd half of 2020, were negotiated a total of:
| BUY | 402,783 shares | € 275,075.79 | 205 executions |
|---|---|---|---|
| SALE | 330,339 shares | € 234,721.02 | 187 executions |
It is also recalled that when the contract was set up, the following resources had been allocated to the liquidity account:
The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
platON™ is Onxeo's proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company's product pipeline.
AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors and the unique ability to abrogate resistance to targeted therapies such as PARPi. The ongoing DRIIV-1b extension study is evaluating the safety and efficacy of AsiDNA™ at a dose of 600 mg in combination with the reference chemotherapy, carboplatin -/+ paclitaxel, in advanced metastatic tumors. Preliminary results from both cohorts showed good tolerability, stabilization of the disease and an increase in treatment duration compared to previous treatments. The ongoing REVOCAN phase 1b/2 study evaluates the effect of AsiDNA™ on the acquired resistance to PARP inhibitor niraparib in relapsed ovarian cancer.
OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.
This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to chapter 3 "Risk Factors" ("Facteurs de Risque") of the Company's universal registration document filed with the Autorité des marchés financiers on April 27, 2020 under number D.20-0362, which is available on the websites of the Autorité des marchés financiers (www.amf-france.org) an the Company (www.onxeo.com).
| Onxeo | Media Relations | Investor Relations / Strategic Communication |
|---|---|---|
| Valerie Leroy, Investor Relations |
Nicolas Merigeau NewCap |
Dušan Orešanský / Emmanuel Huynh NewCap |
| [email protected] | [email protected] | [email protected] |
| +33 1 45 58 76 00 | +33 1 44 71 94 98 | +33 1 44 71 94 92 |
| Investor Relations US Brian Ritchie |
||
| LifeSci Advisors | ||
| [email protected] | ||
| +1 212 915 2578 |
| Buy Side | Sell Side | |||||
|---|---|---|---|---|---|---|
| Number of executions |
Number of shares |
Traded Volume in EUR |
Number of executions |
Number of shares |
Traded volume in EUR |
|
| Total | 122 | 225,004 | 157,757.98 | 118 | 203,522 | 148,483.15 |
| 05/01/2021 | - | - | - | 4 | 3,518 | 2,392.24 |
| 11/01/2021 | - | - | - | 5 | 10,000 | 7,000.00 |
| 13/01/2021 | - | - | - | 2 | 3,031 | 2,152.01 |
| 20/01/2021 | - | - | - | 3 | 1,969 | 1,397.99 |
| 22/01/2021 | 3 | 5,000 | 3,450.00 | - | - | - |
| 26/01/2021 | 4 | 20,000 | 13,400.00 | - | - | - |
| 28/01/2021 | - | - | - | 1 | 1 | 0.67 |
| 29/01/2021 | - | - | - | 2 | 4,553 | 3,050.51 |
| 01/02/2021 | - | - | - | 2 | 5,446 | 3,757.74 |
| 04/02/2021 | - | - | - | 2 | 7,347 | 5,069.43 |
| 05/02/2021 | - | - | - | 13 | 32,653 | 23,836.69 |
| 08/02/2021 | 1 | 5,000 | 3,700.00 | 3 | 5,351 | 4,120.27 |
| 09/02/2021 | 2 | 5,000 | 3,650.00 | - | - | - |
| 10/02/2021 | 8 | 10,000 | 7,200.00 | - | - | - |
| 16/02/2021 | - | - | - | 1 | 1 | 0.74 |
| 18/02/2021 | 6 | 5,001 | 3,550.71 | 1 | 1 | 0.73 |
| 19/02/2021 | 3 | 10,000 | 7,000.00 | 1 | 4,648 | 3,300.08 |
| 23/02/2021 | - | - | - | 4 | 5,000 | 3,600.00 |
| 01/03/2021 | - | - | - | 10 | 15,000 | 11,250.00 |
| 02/03/2021 | 3 | 5,000 | 3,750.00 | 5 | 10,000 | 7,700.00 |
| 03/03/2021 | 8 | 10,000 | 7,400.00 | - | - | - |
| 05/03/2021 | - | - | - | 2 | 10,000 | 7,600.00 |
| 11/03/2021 | 2 | 5,000 | 3,700.00 | - | - | - |
| 17/03/2021 | 4 | 10,000 | 7,300.00 | - | - | - |
| 19/03/2021 | 1 | 5,000 | 3,550.00 | - | - | - |
| 26/03/2021 | - | - | - | 4 | 11,481 | 8,495.94 |
| 29/03/2021 | 2 | 5,000 | 3,650.00 | 1 | 3,519 | 2,639.25 |
| 31/03/2021 | 1 | 5,000 | 3,550.00 | - | - | - |
| 09/04/2021 | - | - | - | 17 | 24,438 | 18,572.88 |
| 12/04/2021 | 7 | 22,201 | 16,872.76 | 9 | 10,562 | 8,343.98 |
| 13/04/2021 | 7 | 17,799 | 12,815.28 | - | - | - |
| 16/04/2021 | - | - | - | 6 | 10,000 | 7,400.00 |
| 19/04/2021 | 2 | 5,000 | 3,600.00 | - | - | - |
| 20/04/2021 | 3 | 5,000 | 3,550.00 | - | - | - |
| 28/04/2021 | 1 | 1 | 0.71 | 1 | 1 | 0.71 |
| 03/05/2021 | 9 | 20,000 | 13,800.00 | - | - | - |
| 17/05/2021 | 4 | 5,000 | 3,350.00 | - | - | - |
| 18/05/2021 | 5 | 5,000 | 3,300.00 | - | - | - |
|---|---|---|---|---|---|---|
| 20/05/2021 | 3 | 10,000 | 6,500.00 | - | - | - |
| 21/05/2021 | - | - | - | 1 | 3,000 | 2,010.00 |
| 25/05/2021 | - | - | - | 2 | 2,000 | 1,340.00 |
| 10/06/2021 | - | - | - | 8 | 15,000 | 10,200.00 |
| 11/06/2021 | 1 | 791 | 522.06 | - | - | - |
| 17/06/2021 | 2 | 932 | 615.12 | - | - | - |
| 18/06/2021 | 7 | 8,277 | 5,380.05 | - | - | - |
| 22/06/2021 | 21 | 20,000 | 12,600.00 | - | - | - |
| 25/06/2021 | 1 | 1 | 0.65 | 1 | 1 | 0.65 |
| 28/06/2021 | - | - | - | 1 | 1,500 | 975.00 |
| 29/06/2021 | - | - | - | 5 | 3,500 | 2,275.00 |
| 30/06/2021 | 1 | 1 | 0.64 | 1 | 1 | 0.64 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.